2011
DOI: 10.2165/11593890-000000000-00000
|View full text |Cite
|
Sign up to set email alerts
|

Once- Versus Twice-Daily Tacrolimus

Abstract: Tacrolimus is a cornerstone immunosuppressant agent in the prevention of organ rejection following transplantation. While typically administered twice daily (Prograf®), a modified-release once-daily formulation (Advagraf®) has recently been developed and licensed for use. To date, the majority of published data relating to the use of Advagraf® have arisen from industry-sponsored clinical trials. These have shown that conversion from Prograf® to Advagraf® on a 1 mg : 1 mg basis in both stable and de novo kidney… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

2
44
0

Year Published

2013
2013
2023
2023

Publication Types

Select...
7
1

Relationship

0
8

Authors

Journals

citations
Cited by 92 publications
(46 citation statements)
references
References 49 publications
2
44
0
Order By: Relevance
“…The dose of prolonged-release tacrolimus is adjusted if C 24 is outside the defined target range. According to most studies, there is a moderate to high correlation between trough level and exposure to prolonged-release tacrolimus [2, 3, 6, 20, 23]. In fact, r 2 of 0.77 in the current study confirms this correlation.…”
Section: Discussionsupporting
confidence: 82%
See 2 more Smart Citations
“…The dose of prolonged-release tacrolimus is adjusted if C 24 is outside the defined target range. According to most studies, there is a moderate to high correlation between trough level and exposure to prolonged-release tacrolimus [2, 3, 6, 20, 23]. In fact, r 2 of 0.77 in the current study confirms this correlation.…”
Section: Discussionsupporting
confidence: 82%
“…While it was developed as an oral twice-daily formulation, a prolonged-release once-daily formulation was launched a few years ago. The efficacy and safety profile of prolonged-release tacrolimus are comparable to that of the twice-daily formulation [3, 9]. Kuijpers et al demonstrated that the once-daily administration of tacrolimus improves adherence, which might ultimately contribute to better graft outcomes [11].…”
Section: Introductionmentioning
confidence: 99%
See 1 more Smart Citation
“…Data from studies in which patients were converted from twice-daily tacrolimus to once-daily tacrolimus (Advagraf) demonstrated the need for continuous dose increases over the first months to maintain consistent therapeutic trough levels [50,51].…”
Section: Drug Profilementioning
confidence: 99%
“…Conventionally, tacrolimus dosage is divided and administered orally every 12 hours to maintain stable trough levels of the drug. The transplant recipients are advised to take tacrolimus on an empty stomach more than one hour before or two to three hours after a meal since oral bioavailability of tacrolimus is variable and absorption of tacrolimus is reduced by food [11, 12]. This requirement may be bothersome to some recipients and thus decrease adherence.…”
Section: Introductionmentioning
confidence: 99%